Plasma levels of IL-6 in patients with untreated major depressive disorder: comparison with catecholamine metabolites

References

• Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743–800.26063472
   PubMed Web of Science ®Google Scholar
• Hamon M, Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:54–63.23602950
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–1366.29477251
   PubMed Web of Science ®Google Scholar
• Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19(1):11–38.7708925
   PubMed Web of Science ®Google Scholar
• Maes M. The immune pathophysiology of major depression In: Honing A, van Praag H, editors. Depression Neurobiological Psychophysiological and Therapeutic Advances. Chester: Wiley; 1997:197–215.
   Google Scholar
• Sluzewska A, Rybakowski J, Bosmans E, et al. Indicators of immune activation in major depression. Psychiatry Res. 1996;64(3):161–167.8944394
   PubMed Web of Science ®Google Scholar
• Berk M, Wadee AA, Kuschke RH, O’Neill-Kerr A. Acute phase proteins in major depression. J Psychosom Res. 1997;43(5):529–534.9394269
   PubMed Web of Science ®Google Scholar
• Frommberger UH, Bauer J, Haselbauer P, Fräulin A, Riemann D, Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci. 1997;247(4):228–233.9332905
   PubMed Web of Science ®Google Scholar
• Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry. 2000;157(5):683–694.10784457
   PubMed Web of Science ®Google Scholar
• Shiepers O, Wichers M, Maes M. Cytokines and major depression, and antidepressants medications: meta-analysis and implication. Biol Psychiatry. 2008;64:527–532.18571629
   PubMed Web of Science ®Google Scholar
• Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Ueda N, Nakamura J. Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(4):722–726.19332097
   PubMed Web of Science ®Google Scholar
• Yoshimura R, Umene-Nakano W, Suzuki A, et al. Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients. Hum Psychopharmacol. 2009;24(6):489–494.19606452
   PubMed Web of Science ®Google Scholar
• Shinkai K, Yoshimura R, Ueda N, Okamoto K, Nakamura J. Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. J Clin Psychopharmacol. 2004;24(1):11–17.14709941
   PubMed Web of Science ®Google Scholar
• Atake K, Yoshimura R, Hori H, Katsuki A, Nakamura J. Catechol-O-methyltransferase Val158Met genotype and the clinical responses to duloxetine treatment or plasma levels of 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in Japanese patients with major depressive disorder. Neuropsychiatr Dis Treat. 2015;11:967–974.25897233
   PubMed Web of Science ®Google Scholar
• Brydon L, Walker C, Wawrzyniak A, et al. Synergistic effects of psychological and immune stressors on inflammatory cytokine and Sickness responses in humans. Brain Behav Immun. 2009;23(2):217–224.18835437
   PubMed Web of Science ®Google Scholar
• Parrado AC, Canellada A, Gentile T, Rey-Roldán EB. Dopamine agonists upregulate IL-6 and IL-8 production in human keratinocytes. Neuroimmunomodulation. 2012;19(6):359–366.23051896
   PubMed Web of Science ®Google Scholar
• Aguilar-Valles A, Jung S, Poole S, Flores C, Luheshi GN. Leptin and interleukin-6 alter the function of mesolimbic dopamine neurons in a rodent model of prenatal inflammation. Psychoneuroendocrinology. 2012;37(7):956–969.22133515
   PubMed Web of Science ®Google Scholar
• Petrulli JR, Kalish B, Nabulsi NB, Huang Y, Hannestad J, Morris ED. Systemic inflammation enhances stimulant-induced striatal dopamine elevation. Transl Psychiatry. 2017;7(3):e1076.28350401
   PubMed Web of Science ®Google Scholar
• Raison CL, Borisov AS, Majer M, et al. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry. 2009;65(4):296–303.18801471
   PubMed Web of Science ®Google Scholar
• Zhang J-C, Yao W, Dong C, et al. Blockade of interleukin-6 receptor in the periphery promotes rapid and sustained antidepressant actions: a possible role of gut-microbiota-brain axis. Transl Psychiatry. 2017;7(5):e1138.28556833
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). Washington, D.C.: American Psychiatric Association; 2000.
   Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.14399272
   PubMed Web of Science ®Google Scholar
• Turton MB, Deegan T. Circadian variations of plasma catecholamine, cortisol and immunoreactive insulin concentrations in supine subjects. Clin Chim Acta. 1974;55(3):389–397.4412449
   PubMed Web of Science ®Google Scholar
• Kendler KS, Mohs RC, Davis KL. The effects of diet and physical activity on plasma homovanillic acid in normal human subjects. Psychiatry Res. 1983;8(3):215–223.6574541
   PubMed Web of Science ®Google Scholar
• Drici MD, Roux M, Candito M, Rimailho A, Morand P, Lapalus P. Influence of beta-blockade on circulating plasma levels of 3-methoxy- 4-hydroxy phenylethylene glycol (MHPG) during exercise in moderate hypertension. Clin Exp Pharmacol Physiol. 1991;18(12): 807–811.1686746
   PubMed Web of Science ®Google Scholar
• Atuk NO, Hanks JB, Weltman J, Bogdonoff DL, Boyd DG, Vance ML. Circulating dihydroxyphenylglycol and norepinephrine concentrations during sympathetic nervous system activation in patients with pheochromocytoma. J Clin Endocrinol Metab. 1994;79(6):1609–1614.7989464
   PubMed Web of Science ®Google Scholar
• Ishikawa A, Miyatake T. Effects of smoking in patients with early-onset Parkinson’s disease. J Neurol Sci. 1993;117(1–2):28–32.8410063
   PubMed Web of Science ®Google Scholar
• Minegishi A, Ishizaki T. Determination of free 3-methoxy-4-hydroxyphenylglycol with several other monoamine metabolites in plasma by high-performance liquid chromatography with amperometric detection. J Chromatogr. 1984;311(1):51–57.6520169
   PubMed Web of Science ®Google Scholar
• Yeung PK, Buckley SJ, Pedder SC, Dingemanse J. Determination of 3,4-dihydroxyphenylacetic acid and 5-hydroxyindoleacetic acid in human plasma by a simple and rapid high-performance liquid chromatography assay. J Pharm Sci. 1996;85(4):451–453.8901087
   PubMed Web of Science ®Google Scholar
• Hori H, Yoshimura R, Katsuki A, et al. Relationships between serum brain-derived neurotrophic factor, plasma catecholamine metabolites, cytokines, cognitive function and clinical symptoms in Japanese patients with chronic schizophrenia treated with atypical antipsychotic monotherapy. World J Biol Psychiatry. 2017;18(5):401–408.27409727
   PubMed Web of Science ®Google Scholar
• Serretti A, Mandelli L, Lorenzi C, et al. Serotonin transporter gene influences the time course of improvement of “core” depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders. Psychiatry Res. 2007;149(1–3):185–193.17157919
   PubMed Web of Science ®Google Scholar
• Yang R, Lin Q, Gao HB, Zhang P. Stress-related hormone norepinephrine induces interleukin-6 expression in ges-1 cells. Braz J Med Biol Res. 2014;47(2):101–109.24519125
   PubMed Web of Science ®Google Scholar
• Li M, Yao W, Li S, Xi J. Norepinephrine induces the expression of interleukin-6 via β-adrenoreceptor-NAD(P)H oxidase system-NF-κB dependent signal pathway in U937 macrophages. Biochem Biophys Res Commun. 2015;460(4):1029–1034.25843793
   PubMed Web of Science ®Google Scholar
• Handley R, Mondelli V, Zelaya F, et al. Effects of antipsychotics on cortisol, interleukin-6 and hippocampal perfusion in healthy volunteers. Schizophr Res. 2016;174(1–3):99–105.27112637
   PubMed Web of Science ®Google Scholar
• Miller AH, Haroon E, Raison CL, Felger JC. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety. 2013;30(4):297–306.23468190
   PubMed Web of Science ®Google Scholar
• Felger JC, Li Z, Haroon E, et al. Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. Mol Psychiatry. 2016;21(10):1358–1365.26552591
   PubMed Web of Science ®Google Scholar
• Yoshimura R, Umene-Nakano W, Hoshuyama T, et al. Plasma levels of brain-derived neurotrophic factor and interleukin-6 in patients with dysthymic disorder: comparison with age- and sex-matched major depressed patients and healthy controls. Hum Psychopharmacol. 2010;25(7–8):566–569.21312291
   PubMed Web of Science ®Google Scholar
• Yoshimura R, Katsuki A, Atake K, Hori H, Igata R, Konishi Y. Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder. Neuropsychiatr Dis Treat. 2017;13:437–441.28243095
   PubMedGoogle Scholar
• Manoharan A, Rajkumar RP, Shewade DG, Sundaram R, Muthuramalingam A, Paul A. Evaluation of interleukin-6 and serotonin as biomarkers to predict response to fluoxetine. Hum Psychopharmacol. 2016; 31(3):178–184.27018372
   PubMed Web of Science ®Google Scholar
• Fornaro M, Martino M, Battaglia F, Colicchio S, Perugi G. Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation. Neuropsychiatr Dis Treat. 2011;7:51–56.21430794
   PubMed Web of Science ®Google Scholar
• Ogawa S, Tsuchimine S, Kunugi H. Cerebrospinal fluid monoamine metabolite concentrations in depressive disorder: a meta-analysis of historic evidence. J Psychiatr Res. 2018;105:137–146.30219563
   PubMed Web of Science ®Google Scholar
• Pech J, Forman J, Kessing LV, Knorr U. Poor evidence for putative abnormalities in cerebrospinal fluid neurotransmitters in patients with depression versus healthy non-psychiatric individuals: a systematic review and meta-analyses of 23 studies. J Affect Disord. 2018;240:6–16.30041075
   PubMed Web of Science ®Google Scholar
• Sasayama D, Hattori K, Wakabayashi C, et al. Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res. 2013;47(3):401–406.23290488
   PubMed Web of Science ®Google Scholar
• Xia Q-R, Liang J, Cao Y, Shan F, Liu Y, Xu Y-Y. Increased plasma nesfatin-1 levels may be associated with corticosterone, IL-6, and CRP levels in patients with major depressive disorder. Clin Chim Acta. 2018; 480:107–111.29427582
   PubMed Web of Science ®Google Scholar
• Fan N, Luo Y, Ou Y, He H. Altered serum levels of TNF-α, IL-6, and IL-18 in depressive disorder patients. Hum Psychopharmacol. 2017;32(4): e2588.
   Web of Science ®Google Scholar
• Yoshimura R, Hori H, Ikenouchi-Sugita A, et al. Plasma levels of interleukin-6 and selective serotonin reuptake inhibitor response in patients with major depressive disorder. Hum Psychopharmacol. 2013; 28(5):466–470.23813968
   PubMed Web of Science ®Google Scholar
• Tucker P, Pfefferbaum B, Nitiéma P, Khan Q, Aggarwal R, Walling EE. Possible link of interleukin-6 and interleukin-2 with psychiatric diagnosis, ethnicity, disaster or BMI. Cytokine. 2017;96:247–252.28486207
   PubMed Web of Science ®Google Scholar